Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00533910 · ClinicalTrials.gov registry record · NA
Rifaximin in Minimal Hepatic Encephalopathy
A NA study of Hepatic Encephalopathy, sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT00533910 is a NA study of Hepatic Encephalopathy that has completed, run by Hunter Holmes Mcguire Veteran Affairs Medical Center. The registered enrollment target is 42 participants, below the 173-participant average among 12 other Hepatic Encephalopathy trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00533910, a NA study of Hepatic Encephalopathy, has completed, sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether alteration of gut flora with rifaximin can lead to improvement in driving performance, psychometric test performance, and quality of life in patients with minimal hepatic encephalopathy (MHE) and cirrhosis in a randomized, blinded, placebo-controlled trial.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Rifaximin
Study Locations (1)
Virginia
- Hunter Holmes McGuire VA Medical Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00533910
The ClinicalTrials.gov registry entry for NCT00533910 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 173-participant average among 12 other Hepatic Encephalopathy trials with a reported enrollment target (76% lower). The listed sponsor is Hunter Holmes Mcguire Veteran Affairs Medical Center, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatic Encephalopathy appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00533910 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT00533910 about?
NCT00533910 is a clinical study titled "Rifaximin in Minimal Hepatic Encephalopathy". The purpose of this study is to determine whether alteration of gut flora with rifaximin can lead to improvement in driving performance, psychometric test performance, and quality of life in patients with minimal hepatic encephalopathy (MHE) and cirrhosis in a randomized, blinded, placebo-controlled...
What is the current status of trial NCT00533910?
This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2007-10. Estimated completion is 2010-05.
What conditions does trial NCT00533910 study?
This clinical trial studies the following conditions: Hepatic Encephalopathy.
What interventions are being tested in trial NCT00533910?
The interventions under investigation include: placebo (DRUG), Rifaximin (DRUG).
Who is sponsoring clinical trial NCT00533910?
This trial is sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00533910 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Encephalopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy
RECRUITING · NA
-
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
RECRUITING · NA
-
Affect of Melatonin on Sleep and Cognition in Cirrhosis
RECRUITING · NA
-
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
RECRUITING · Phase 2
-
TReatment for ImmUne Mediated PathopHysiology
RECRUITING · Phase 2
-
Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.